DealsJun 7, 2026, 07:31 PM
LENZ Therapeutics to get up to $85M in China VIZZ deal
AI Summary
LENZ Therapeutics announced that Everest Medicines acquired the rights to develop, manufacture, and commercialize VIZZ (LNZ100) in Greater China from Corxel Pharmaceuticals. This agreement transfers the existing license rights and obligations to Everest. LENZ is eligible to receive up to $85.0 million in remaining regulatory and sales milestones, along with tiered mid single-digit to low double-digit royalties on net sales in the region. The New Drug Application for LNZ100 in China was submitted in September 2025, with approval anticipated in Q1 2027.
Key Highlights
- Everest Medicines acquired VIZZ (LNZ100) rights in Greater China.
- LENZ eligible for up to $85.0 million in regulatory and sales milestones.
- LENZ to receive tiered mid single-digit to low double-digit royalties.
- LNZ100 New Drug Application submitted in China in September 2025.
- China approval for LNZ100 anticipated in Q1 2027.
- VIZZ (LNZ100) is an eye drop for presbyopia treatment.
Price Impact
More from LENZ